Photo: Kwanchai Lerttanapunyaporn/EyeEm/Getty Images
Cardiovascular disease-focused Cleerly scored $192 million in Series C financing, a little more than a year after the company launched with a $43 million Series B.
The latest round, led by T. Rowe Price and Fidelity Management and Research Company, brings Cleerly's total raise to $248 million.
Other participants in the round include Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
The company offers an AI-backed tool that evaluates CT angiograms for plaque build-up on the heart arteries' walls, which Cleerly pitches as a way to catch heart disease early. It will use the Series C capital to expand its team and commercial capabilities as well as invest in research.
"At Cleerly, we are passionate about our mission to create a new standard of care for heart disease," CEO and founder Dr. James Min said in a statement. "We are grateful for this round of financing that will further enable our work and believe it provides a resounding vote of confidence in our vision for the future of cardiovascular care.
"The status quo for heart health simply isn’t good enough – for patients, providers, or payors – and our proven approach to examining for early signs of heart disease through the build-up of arterial plaque promises to deliver the change we need right now."
Elation Health, which offers tools for telehealth, patient engagement, and an EHR geared toward primary care providers, raised $50 million in Series D funding.
The round was led by Generation Investment Management and Ascension Ventures, with participation from Threshold Ventures, Ascend Partners, and individual investors, including Firefly Health CEO Fay Rotenberg, and former athenahealth CEO and founder Jonathan Bush.
Elation most recently scored $40 million in Series C financing in 2020. The latest raise brings its total funding pot to $108.5 million.
Patient intake chatbot Health Note closed a $17 million Series A funding round led by SignalFire.
Other investors in the round include UnityPoint Health, Northwell Holdings and Cedars Sinai Health Ventures.
The startup offers a platform that can message patients to confirm their appointments, discuss health history and concerns, and then input that information into the EHR before their visit. Health Note will use the investment to speed market expansion, add EHR integrations, and invest in research and development to add to their tools.
"The vision for Health Note has always been to support care providers by empowering patients to create and interact with their health data before the visit starts, thus reducing the growing documentation burden that frustrates the vast majority of doctors and care teams," CEO and cofounder Dr. Joshua Reischer said in a statement.
"The additional funding will help Health Note replicate its early success with mid-size practices and health systems at scale, which is sorely needed as our health system continues to operate with limited staff."
Summer Health raised $7.5 million in seed funding for its messaging service that allows parents to chat with pediatricians about their child's health and development. The service is now available in public beta testing.
The round was led by Alfred Lin at Sequoia Capital and Deena Shakir at Lux Capital, with participation from Box Group, Metrodora Ventures, Shrug Capital, Springbank Collective, Coalition Operators, Moving Ventures, Maven founder and CEO Kate Ryder, Hims & Hers founder and CEO Andrew Dudum, Mos founder and CEO Amira Yahyaoui, and digital health investor Alyssa Jaffee.
RxLive, which offers tools for telepharmacy and medication management, scooped up $5 million in a Series A funding round, led by SpringTide, with participation from Cardinal Health.
The startup plans to use the funds to hire for its engineering, analytics, and sales and marketing teams, and to improve its medication management platform.
"With the move to value-based care, the overnight adoption of telemedicine, and growing importance and emphasis on managing pharmacy spend, RxLive is putting clinical pharmacists back where they belong," RxLive cofounder and chief pharmacy officer Kristen Engelen said in a statement.
"We give patients the one-on-one medication expertise and attention they need to improve quality of life, and the technology and services healthcare organizations need to improve outcomes."